Translations:SGLT2 inhibitor/3/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
15,166 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 19:46, 12 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (SGLT2 inhibitor)
==Medical uses==
The 2022 [[American Diabetes Association|ADA]] standards of medical care in diabetes include SGLT2 inhibitors as a first line [[pharmacological therapy]] for type 2 diabetes (usually together with metformin), specifically in patients with [[chronic kidney disease]], [[cardiovascular disease]] or [[heart failure]].

Medical uses

The 2022 ADA standards of medical care in diabetes include SGLT2 inhibitors as a first line pharmacological therapy for type 2 diabetes (usually together with metformin), specifically in patients with chronic kidney disease, cardiovascular disease or heart failure.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:SGLT2_inhibitor/3/en&oldid=113832"